New treatment approach for Alzheimer's disease using VGF delivery to the brain
Official title: Therapeutic Strategy to Treat Alzheimer's Disease by VGF Delivery into Brain
Funded at North Dakota State University · NIH-11088177 · Data updated 2026-11-12
This study is testing a new gene therapy for Alzheimer's disease that delivers a special protein directly into the brain using tiny particles, and it’s designed to help improve memory and thinking skills for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | North Dakota State University NIH-funded |
| Lab location | 1 site (Fargo, United States) |
| Project start | September 16, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $606,012 |
| NIH project number | 5R01AG083981-03 |
| Project ID | NIH-11088177 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those experiencing significant cognitive decline associated with aging.
✕Less likely to help
Patients with early-stage Alzheimer's or those without cognitive impairment may not receive direct benefits from this research.
What this research studies
This research focuses on developing a novel gene therapy for Alzheimer's disease by delivering a protein called VGF directly into the brain. The approach involves creating specialized nanoparticles that can safely cross the blood-brain barrier and target brain cells. By using both intravenous and intranasal methods for administration, the therapy aims to enhance neuron growth and survival, potentially improving cognitive functions affected by Alzheimer's. Patients may be monitored for changes in memory and cognitive abilities as part of the treatment process.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that improves cognitive function and slows the progression of Alzheimer's disease.
How similar studies have gone: While gene therapy for Alzheimer's is a relatively novel approach, preliminary studies have shown promise in similar methodologies, indicating potential for success.
Where this research is happening
-
North Dakota State University
Fargo, United States Active
Researchers
- Principal investigator: Singh, Jagdish — North Dakota State University
- Study coordinator: Singh, Jagdish
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.